Dalcetrapib or JTT-705 is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012. The drug was aimed at raising the blood levels of \"good cholesterol\" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health.

CAS：211513-37-0
中文别名：CETP抑制剂;
英文别名：Unii-3D050liq3h;JTT-705;
分子式：C23H35NO2S
分子量：389.595
精确质量：389.239
Psa：71.47
Logp：6.7496

MDL号：MFCD06407886

密度：1.066 g/cm3
沸点：528.912ºC at 760 mmHg
闪点：273.676ºC